| 000 | 01513 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250515163822.0 | ||
| 264 | 0 | _c20090717 | |
| 008 | 200907s 0 0 fre d | ||
| 022 | _a1769-6917 | ||
| 024 | 7 |
_a10.1684/bdc.2009.0835 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLaigle-Donadey, F | |
| 245 | 0 | 0 |
_a[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas]. _h[electronic resource] |
| 260 |
_bBulletin du cancer _cMar 2009 |
||
| 300 |
_a291-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xtherapeutic use |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aBrain Neoplasms _xblood supply |
| 650 | 0 | 4 |
_aCamptothecin _xanalogs & derivatives |
| 650 | 0 | 4 |
_aCombined Modality Therapy _xmethods |
| 650 | 0 | 4 |
_aDacarbazine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aGlioblastoma _xblood supply |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 |
_aNeovascularization, Pathologic _xdrug therapy |
| 650 | 0 | 4 | _aTemozolomide |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 700 | 1 | _aDehais, C | |
| 700 | 1 | _aMazeron, J-J | |
| 700 | 1 | _aSanson, M | |
| 773 | 0 |
_tBulletin du cancer _gvol. 96 _gno. 3 _gp. 291-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1684/bdc.2009.0835 _zAvailable from publisher's website |
| 999 |
_c18755508 _d18755508 |
||